Edition:
United States

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

5.45USD
20 Jul 2018
Change (% chg)

$-0.15 (-2.68%)
Prev Close
$5.60
Open
$5.63
Day's High
$5.64
Day's Low
$5.32
Volume
12,383
Avg. Vol
49,559
52-wk High
$11.65
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations
Thursday, 10 May 2018 04:05pm EDT 

May 10 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52 FROM CONTINUING OPERATIONS.  Full Article

Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops
Thursday, 22 Mar 2018 04:05pm EDT 

March 22 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.40 FROM CONTINUING OPERATIONS.CALADRIUS - ‍AS OF DEC 31, 2017, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $60.1 MILLION VERSUS $7.1 MILLION AS OF DEC 31, 2016​.CALADRIUS BIOSCIENCES - ‍CONFIDENT THAT CASH BALANCES, ADDITIONAL GRANT FUNDING WILL ALLOW IT TO FUND ITS CURRENT BUSINESS PLAN BEYOND 2019​.  Full Article

Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program
Tuesday, 6 Mar 2018 08:00am EST 

March 6 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA.CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM.CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES.CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM.  Full Article

Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co
Thursday, 8 Feb 2018 06:52pm EST 

Feb 8 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION.  Full Article

Caladrius Biosciences reports 2017 third quarter results
Thursday, 9 Nov 2017 04:11pm EST 

Nov 9 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.  Full Article

Caladrius Biosciences files for resale of co's common stock‍​ by the selling stockholders
Wednesday, 6 Sep 2017 06:01am EDT 

Sept 6 (Reuters) - Caladrius Biosciences Inc :Files for resale of up to 932,204 shares of Co's common stock‍​ by the selling stockholders - SEC filing.  Full Article

Caladrius Biosciences Q2 loss per share $0.22 from continuing operations
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 second quarter results.Q2 loss per share $0.22 from continuing operations.  Full Article

Caladrius Biosciences says 50 pct of subjects have been treated in the phase 2 clinical trial of CLBS03
Wednesday, 19 Jul 2017 08:00am EDT 

July 19 (Reuters) - Caladrius Biosciences Inc ::Caladrius Biosciences announces that 50 pct of subjects have been treated in the phase 2 clinical trial of clbs03 for type 1 diabetes.Caladrius - interim analysis of early therapeutic effect to occur after 6 month post-treatment follow-up visit,results in late 2017/early 2018.  Full Article

Caladrius Biosciences Q1 loss per share $1.12
Monday, 15 May 2017 05:07pm EDT 

May 15 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences announces 2017 first quarter financial results.Q1 revenue rose 6 percent to $7.9 million.Q1 loss per share $1.12.Expects to provide more specifics on cash usage for balance of 2017 after closing of Hitachi transaction.  Full Article

Caladrius Biosciences Inc says addition of four clinical sites for ongoing phase 2 study of CLBS03 in T1D
Monday, 3 Apr 2017 07:30am EDT 

Caladrius Biosciences Inc : Caladrius Biosciences Inc says addition of four clinical sites, including Joslin Diabetes Center, for ongoing phase 2 study of CLBS03 in T1D . Caladrius Biosciences Inc says expects to reach important milestone of treating 50% of subjects by mid-2017 .Caladrius Biosciences Inc says enrollment of 70(th) subject in study, expected to occur in mid-2017, will trigger an additional infusion of capital.  Full Article